Neurology
Preclinical Alzheimer's Disease
3
Pipeline Programs↗
3
Active Trials↗
1
Companies Involved↗
Preclinical Alzheimer's Disease is an early-stage landscape with 3 programs across 1 company. The most active players are Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
4
clinical trials
Active, not recruiting1 · 25%
Completed1 · 25%
Enrolling by invitation1 · 25%
Recruiting1 · 25%
Clinical Trials
Trial Activity
Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1
Enrolling by invitation·—·Phase 2·NCT07167966·450 enrolled
The Alzheimer's Disease Tau Platform Clinical Trial
Recruiting·—·Phase 2·NCT06957418·900 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)